|
Clinical applications of antiplatelet therapy.
Rev Cardiovasc Med. 2006 Ene; 7(3):130-46.
Wiviott SD, Tantry US, Gurbel PA |
|
Lipoprotein-associated proteins involved in platelet signaling.
Pathophysiol Haemost Thromb. 2006 Ene; 35(3-4):305-13.
Korporaal SJ, Akkerman JW. |
|
Lipoprotein(a) and thrombocytes: potential mechanisms underlying cardiovascular risk.
Pathophysiol Haemost Thromb. 2006 Ene; 35(3-4):314-21.
Discepolo W, Wun T, Berglund L. |
|
Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2.
Stroke. 2006 Ene; 37(1):134-8.
Ariesen MJ, Algra A, Kappelle LJ. |
|
Molecular defects in the ABCA1 pathway affect platelet function.
Pathophysiol Haemost Thromb. 2006 Ene; 35(1-2):166-74.
Schmitz G, Schambeck CM. |
|
Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
Am J Cardiol. 2006 Ene; 97(1):38-43.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C. |
|
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
Am Heart J. 2006 Ene; 151(1):219-27.
Mahoney EM, Mehta S, Yuan Y, Jackson J, Chen R, Gabriel S, Lamy A, Culler S, Caro J, Yusuf S, Weintraub WS; CURE Study Investigators. |
|
Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death.
Stroke. 2006 Ene; 37(1):129-33.
Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen ER, Hillbom M. |
|
Platelet activation and progression to complications.
Rev Cardiovasc Med. 2006 Ene; 7(2):75-81.
Kereiakes DJ, Michelson AD. |
|
Low-density lipoprotein-lowering medication and platelet function.
Pathophysiol Haemost Thromb. 2006 Ene; 35(3-4):346-54.
Ferroni P, Basili S, Santilli F, Davi G. |
|
The platelet ATP and ADP receptors.
Curr Pharm Des. 2006 Ene; 12(7):859-75. Review Dic
Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. |
|
Antiplatelet therapy in children.
Thromb Res. 2006 Ene; 118(1):75-83. Epub 2005 Feb 1. Dic
Israels SJ, Michelson AD. |
|
Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems.
Ann Med. 2006 Ene; 38(3):162-72. Review Dic
Horiuchi H. |
|
Aspirin and clopidogrel resistance: an emerging clinical entity.
Eur Heart J. 2005 Dic;
Wang TH, Bhatt DL, Topol EJ. |
|
Antiplatelet versus anticoagulant therapies in advanced age: An unfinished task.
Int J Cardiol. 2005 Dic;
Garcia-Honrubia A, Roldan V, Climent V, Sogorb F, Marin F. |
|
Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study.
Thromb Res. 2005 Dic;
Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, Berti S, Clerico A, Biagini A. |
|
Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial.
J Thromb Haemost. 2005 Dic; 3(12):2649-55.
Eikelboom JW, Hankey GJ, Thom J, Claxton A, Yi Q, Gilmore G, Staton J, Barden A, Norman PE. |
|
Low-dose aspirin for the prevention of atherothrombosis.
N Engl J Med. 2005 Dic; 353(22):2373-83.
Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. |
|
Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin.
J Thromb Haemost. 2005 Dic; 3(12):2784-9.
Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, Trifiro E, Di Renzo L, Violi F. |
|
Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
J Am Coll Cardiol. 2005 Nov; 46(10):1833-7.
Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, Han KH, Lee CW, Kang DH, Song JK, Kim JJ, Park SJ. |
